Kunal Nitinkumar Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kunal Nitinkumar Patel has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Monil Majmundar
Department of Cardiovascular Medicine University of Kansas Medical Center Kansas City KS USA
10 shared publications - Kamal Gupta
University of Kansas Medical Center
8 shared publications Rajkumar Doshi
Department of Cardiology, Atlantic Medical Group Cardiology, Hackettstown, NJ, USA
7 shared publications- Ankur Kalra
SUNY Upstate Medical University
6 shared publications Monil Majmundar
Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, USA
6 shared publicationsAshish Kumar
Department of Internal Medicine, Cleveland Clinic Akron General , Akron, OH, USA
4 shared publications
Latest Publications
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (6) , e250071
Comparison of Diagnostic Parameters Using Cardiac CT–derived Aortic Valve Area and Aortic Valve Calcium Scores for Low-Gradient Aortic Stenosis
In low-gradient aortic stenosis, diagnostic strategies combining cardiac CT–derived aortic valve area with aortic valve calcium (AVC) or AVC density scores showed comparable diagnostic performance to baseline models of AVC alone or AVC with aortic valve area from echocardiography.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (6) , e250071
Comparison of Diagnostic Parameters Using Cardiac CT–derived Aortic Valve Area and Aortic Valve Calcium Scores for Low-Gradient Aortic Stenosis
In low-gradient aortic stenosis, diagnostic strategies combining cardiac CT–derived aortic valve area with aortic valve calcium (AVC) or AVC density scores showed comparable diagnostic performance to baseline models of AVC alone or AVC with aortic valve area from echocardiography.
- Open Access
Trends and Outcomes of Carotid Revascularization for Asymptomatic Carotid Stenosis Among End-Stage-Kidney-Disease Patients on Dialysis from 2010 to 2019
INTRODUCTION The role of carotid revascularization for asymptomatic carotid artery stenosis (ACAS) in dialysis-dependent end-stage kidney disease (ESKD) patients remains poorly defined, as these patients have high periprocedural risks and limited long-term survival. This study evaluated the trends in carotid revascularization in this group and studied associated short- and long-term outcomes. METHODS We analyzed the United States Renal Data System (USRDS) to study dialysis-dependent ESKD patients with ACAS who underwent carotid endarterectomy (CEA) or carotid artery stenosis (CAS) between 2010 and 2019. Primary outcomes included trends in CEA and CAS utilization, 30-day stroke or death rates. Secondary outcomes were in-hospital and one-year stroke or death rates. RESULTS Among 11,405 ESKD patients on dialysis with ACAS, 4954 underwent carotid revascularization (4098 CEA; 856 CAS). CEA rates reduced by 55% and CAS by 50% between 2010 and 2019. CAS was associated with a higher 30-day composite stroke or death rate (7.13% vs 4.5%; P=0.0014), in-hospital stroke or death rate (3.39% vs 2.22%, P=0.0433), and 1-year stroke or death rate (33.1% vs 25.4%, PCONCLUSION Carotid revascularization rates for ACAS have declined among dialysis-dependent ESKD patients, yet both CEA and CAS are associated with significant procedure-related stroke and death risk. These support a cautious approach and underscore the need for a more selective and individualized shared decision-making approach in this high-risk population.
Open AccessTrends and Outcomes of Carotid Revascularization for Asymptomatic Carotid Stenosis Among End-Stage-Kidney-Disease Patients on Dialysis from 2010 to 2019
INTRODUCTION The role of carotid revascularization for asymptomatic carotid artery stenosis (ACAS) in dialysis-dependent end-stage kidney disease (ESKD) patients remains poorly defined, as these patients have high periprocedural risks and limited long-term survival. This study evaluated the trends in carotid revascularization in this group and studied associated short- and long-term outcomes. METHODS We analyzed the United States Renal Data System (USRDS) to study dialysis-dependent ESKD patients with ACAS who underwent carotid endarterectomy (CEA) or carotid artery stenosis (CAS) between 2010 and 2019. Primary outcomes included trends in CEA and CAS utilization, 30-day stroke or death rates. Secondary outcomes were in-hospital and one-year stroke or death rates. RESULTS Among 11,405 ESKD patients on dialysis with ACAS, 4954 underwent carotid revascularization (4098 CEA; 856 CAS). CEA rates reduced by 55% and CAS by 50% between 2010 and 2019. CAS was associated with a higher 30-day composite stroke or death rate (7.13% vs 4.5%; P=0.0014), in-hospital stroke or death rate (3.39% vs 2.22%, P=0.0433), and 1-year stroke or death rate (33.1% vs 25.4%, PCONCLUSION Carotid revascularization rates for ACAS have declined among dialysis-dependent ESKD patients, yet both CEA and CAS are associated with significant procedure-related stroke and death risk. These support a cautious approach and underscore the need for a more selective and individualized shared decision-making approach in this high-risk population.
- Open Access
- 22 August 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 23, 101263
Impact of mode of delivery on maternal and fetal outcomes in pregnant patients with heart failure or pulmonary hypertension
- 22 August 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 23, 101263
Open AccessImpact of mode of delivery on maternal and fetal outcomes in pregnant patients with heart failure or pulmonary hypertension
- Open Access
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e040026
Acute Limb Ischemia After Percutaneous Coronary Intervention for Stable Coronary Artery Disease
Introduction: Despite its severity, there is limited information on the incidence, predictors, and outcomes of acute limb ischemia (ALI) after percutaneous coronary interventions (PCIs) in stable coronary artery disease. Methods and Results: We included all patients undergoing PCI for stable coronary artery disease in the Nationwide Readmissions Database from 2016 to 2020, identifying them using appropriate International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ), codes. Our primary outcomes were the incidence and predictors of ALI. A total of 629 656 patients underwent PCI for stable coronary artery disease. Of this sample, 3456 (0.55%) had ALI. Peripheral artery disease was the strongest predictor of post‐PCI ALI (odds ratio, 53.03 [95% CI, 43.76–64.28], P <0.001). Patients with ALI had a 1.6 times greater risk of in‐hospital mortality and a 4.7 times greater risk of in‐hospital major amputation. Forty point nine percent of patients with ALI underwent embolectomy, while 11.6% received thrombolysis. Outcomes were similar between ALI of the upper and lower extremity. Patients undergoing embolectomy had greater in‐hospital mortality, while the thrombolysis group had greater in‐hospital major amputation. Conclusion: ALI is an uncommon complication of PCI but is associated with a high risk of mortality and amputation. Peripheral artery disease is the strongest predictor of post‐PCI ALI.
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e040026
Open AccessAcute Limb Ischemia After Percutaneous Coronary Intervention for Stable Coronary Artery Disease
Introduction: Despite its severity, there is limited information on the incidence, predictors, and outcomes of acute limb ischemia (ALI) after percutaneous coronary interventions (PCIs) in stable coronary artery disease. Methods and Results: We included all patients undergoing PCI for stable coronary artery disease in the Nationwide Readmissions Database from 2016 to 2020, identifying them using appropriate International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ), codes. Our primary outcomes were the incidence and predictors of ALI. A total of 629 656 patients underwent PCI for stable coronary artery disease. Of this sample, 3456 (0.55%) had ALI. Peripheral artery disease was the strongest predictor of post‐PCI ALI (odds ratio, 53.03 [95% CI, 43.76–64.28], P <0.001). Patients with ALI had a 1.6 times greater risk of in‐hospital mortality and a 4.7 times greater risk of in‐hospital major amputation. Forty point nine percent of patients with ALI underwent embolectomy, while 11.6% received thrombolysis. Outcomes were similar between ALI of the upper and lower extremity. Patients undergoing embolectomy had greater in‐hospital mortality, while the thrombolysis group had greater in‐hospital major amputation. Conclusion: ALI is an uncommon complication of PCI but is associated with a high risk of mortality and amputation. Peripheral artery disease is the strongest predictor of post‐PCI ALI.
- 13 March 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (2) , 138-146
Prognostic value of the Hospital Frailty Risk Score (HFRS) and outcomes in peripheral artery disease and end-stage kidney disease
Background: Peripheral artery disease (PAD) and end-stage kidney disease (ESKD) are independent risk factors affecting outcomes like in-hospital mortality. The role of a frailty index in prognosticating outcomes in patients with ESKD and PAD is unknown. We aim to assess the prognostic value of the Hospital Frailty Risk Score (HFRS) and its association with outcomes in these patients. Methods: We identified patients with PAD using data from the United States Renal Data System (USRDS) for the years 2015–2018. These patients were stratified into three categories of frailty risk based on their HFRS, a validated frailty assessment tool using ICD-10 codes: low (< 5), intermediate (5–10), and high risk (> 10) and based on revascularization or not. Primary outcomes included in-hospital mortality and composite of mortality or major amputation. Secondary outcomes encompassed postdischarge mortality and composite of mortality or major amputation at 1 year. Results: Out of 122,649 patients with PAD and ESKD, 4118 underwent revascularization and 118,531 did not. In-hospital outcomes demonstrated a nonlinear relationship and postdischarge outcomes displayed a nearly linear relationship with HFRS, regardless of revascularization status. In both cohorts, the high-risk group was associated with a significantly higher risk of in-hospital mortality/amputation (revascularization: odds ratio [OR] 4.6, 95% CI 3.3–6.2, p < 0.001; no revascularization: OR 3.1, 95% CI 2.8–3.3, p < 0.001) and mortality (revascularization: OR 5.5, 95% CI 3.4–8.7, p < 0.001; no revascularization: OR 5.1, 95% CI 4.6–5.6, p < 0.001) compared with the low-risk group. Conclusion: In patients with ESKD and PAD, the HFRS serves as a valuable predictor of mortality and amputation irrespective of revascularization. This information can support informed decision-making.
- 13 March 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (2) , 138-146
Prognostic value of the Hospital Frailty Risk Score (HFRS) and outcomes in peripheral artery disease and end-stage kidney disease
Background: Peripheral artery disease (PAD) and end-stage kidney disease (ESKD) are independent risk factors affecting outcomes like in-hospital mortality. The role of a frailty index in prognosticating outcomes in patients with ESKD and PAD is unknown. We aim to assess the prognostic value of the Hospital Frailty Risk Score (HFRS) and its association with outcomes in these patients. Methods: We identified patients with PAD using data from the United States Renal Data System (USRDS) for the years 2015–2018. These patients were stratified into three categories of frailty risk based on their HFRS, a validated frailty assessment tool using ICD-10 codes: low (< 5), intermediate (5–10), and high risk (> 10) and based on revascularization or not. Primary outcomes included in-hospital mortality and composite of mortality or major amputation. Secondary outcomes encompassed postdischarge mortality and composite of mortality or major amputation at 1 year. Results: Out of 122,649 patients with PAD and ESKD, 4118 underwent revascularization and 118,531 did not. In-hospital outcomes demonstrated a nonlinear relationship and postdischarge outcomes displayed a nearly linear relationship with HFRS, regardless of revascularization status. In both cohorts, the high-risk group was associated with a significantly higher risk of in-hospital mortality/amputation (revascularization: odds ratio [OR] 4.6, 95% CI 3.3–6.2, p < 0.001; no revascularization: OR 3.1, 95% CI 2.8–3.3, p < 0.001) and mortality (revascularization: OR 5.5, 95% CI 3.4–8.7, p < 0.001; no revascularization: OR 5.1, 95% CI 4.6–5.6, p < 0.001) compared with the low-risk group. Conclusion: In patients with ESKD and PAD, the HFRS serves as a valuable predictor of mortality and amputation irrespective of revascularization. This information can support informed decision-making.
- Open Access
- 16 January 2025
- Published by Elsevier in Indian Heart Journal
- Vol. 77 (1) , 45-47
Impact of sarcoidosis in patients undergoing aortic valve replacement: Insight from nationwide readmission database 2016–2019
- 16 January 2025
- Published by Elsevier in Indian Heart Journal
- Vol. 77 (1) , 45-47
Open AccessImpact of sarcoidosis in patients undergoing aortic valve replacement: Insight from nationwide readmission database 2016–2019
- Open Access
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036963
Prognostic Value of Hospital Frailty Risk Score and Clinical Outcomes in Critical Limb‐Threatening Ischemia and End‐Stage Kidney Disease
Background: End‐stage kidney disease (ESKD) is commonly associated with critical limb‐threatening ischemia (CLTI) and frailty. Yet there are no specific tools to predict outcomes of CLTI in ESKD, particularly those that incorporate frailty. We aimed to assess the utility of the medical record–based Hospital Frailty Risk (HFR) score in predicting outcomes of CLTI in ESKD. Methods and Results: We identified patients with ESKD diagnosed with CLTI from the US Renal Data System from 2015 to 2018. These patients were categorized into 3 frailty risk groups on the basis of their HFR scores: low (10), and on the basis of whether they underwent revascularization (endovascular revascularization [ER]/surgical revascularization [SR]) or not (no revascularization). Primary outcomes of interest included in‐hospital composite of death or major amputation and in‐hospital death. We included 49 454 eligible patients, with ER/SR cohort including 19.8% (n=9777). A total of 88.4% (ER/SR) and 90.0% (no revascularization) were frail on the HFR scale. We found a nonlinear association between HFR score and in‐hospital adverse outcomes. In both cohorts, intermediate and high‐risk HFR scores were associated with greater risk of in‐hospital death (high‐risk, ER/SR: odds ratio, 2.7 [95% CI, 1.6–4.8]; P P P P <0.0001). Conclusions: The HFR score can predict risk of in‐hospital death and composite of death or major amputation in patients with ESKD and CLTI. Further data are needed to determine the utility of the HFR score in this population.
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036963
Open AccessPrognostic Value of Hospital Frailty Risk Score and Clinical Outcomes in Critical Limb‐Threatening Ischemia and End‐Stage Kidney Disease
Background: End‐stage kidney disease (ESKD) is commonly associated with critical limb‐threatening ischemia (CLTI) and frailty. Yet there are no specific tools to predict outcomes of CLTI in ESKD, particularly those that incorporate frailty. We aimed to assess the utility of the medical record–based Hospital Frailty Risk (HFR) score in predicting outcomes of CLTI in ESKD. Methods and Results: We identified patients with ESKD diagnosed with CLTI from the US Renal Data System from 2015 to 2018. These patients were categorized into 3 frailty risk groups on the basis of their HFR scores: low (10), and on the basis of whether they underwent revascularization (endovascular revascularization [ER]/surgical revascularization [SR]) or not (no revascularization). Primary outcomes of interest included in‐hospital composite of death or major amputation and in‐hospital death. We included 49 454 eligible patients, with ER/SR cohort including 19.8% (n=9777). A total of 88.4% (ER/SR) and 90.0% (no revascularization) were frail on the HFR scale. We found a nonlinear association between HFR score and in‐hospital adverse outcomes. In both cohorts, intermediate and high‐risk HFR scores were associated with greater risk of in‐hospital death (high‐risk, ER/SR: odds ratio, 2.7 [95% CI, 1.6–4.8]; P P P P <0.0001). Conclusions: The HFR score can predict risk of in‐hospital death and composite of death or major amputation in patients with ESKD and CLTI. Further data are needed to determine the utility of the HFR score in this population.
- Open Access
- 22 May 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (6) , 100323
National Trends, In-Hospital Mortality, and Outcomes of Atrial Septal Defect/Patent Foramen Ovale Closure Procedure: An Analysis From the National Inpatient Sample
- 22 May 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (6) , 100323
Open AccessNational Trends, In-Hospital Mortality, and Outcomes of Atrial Septal Defect/Patent Foramen Ovale Closure Procedure: An Analysis From the National Inpatient Sample
- Open Access
Prevalence and Clinical Outcomes of Acute Noncardiac Organ Failure among Non-Acute Myocardial Infarction Cardiogenic Shock: A Nationwide Cohort Analysis
Background Noncardiac organ failure often complicates cardiogenic shock (CS). The results of cardiogenic shock caused by noncardiac organ failures in patients without acute myocardial infarction (AMI) are not well documented. Methods We examined the National Inpatient Sample (NIS) data from 2016 to 2020 to identify cases of CS and non-AMI CS-related hospitalizations. We divided both cohorts based on the number of acute noncardiac organ failures and evaluated the influence of organ failure on the primary outcome, which was in-hospital mortality. Results A total of 599,210 (100%) cardiogenic shock and 366,905 (61.2%) non-AMI CS hospitalizations were identified. Among those with non-AMI CS, 58,965 (16.07%) had no organ failure, 121,845 (33.21%) had a single organ failure, and 186,095 (50.72%) had a multiorgan failure. Acute Kidney Injury (AKI) was the most common non-cardiac organ failure (38.1%). Multiorgan failure was associated with an increased risk of in-hospital mortality (aOR: 4.91, 95% CI: 4.72-5.06, p Conclusions In non-acute myocardial infarction and all cardiogenic shock patients, AKI is the most common type of organ failure, and neurological failure was associated with the highest mortality rate. The presence of noncardiac multiorgan failure was found to be strongly associated with a higher mortality rate. This risk increased as more organs were affected. What Is New? ● Non-AMI patients bear a considerable load of non-cardiac organ failure, where AKI is the most prevalent form of organ failure. Additionally, neurological failure has the highest in-hospital mortality rate. ● A predictor model for calculating the probability of in-hospital mortality in all CS patients. ● Non-AMI cardiogenic shock and all cardiogenic shock patients are associated with higher morbidity, mortality, and resource utilization, as well as advanced circulatory support therapies, which increase as the number of affected organs increases. What are the Clinical Implications? ● Multi-organ failure in non-AMI CS can have worse cardiovascular outcomes. ● A multidisciplinary team’s involvement in managing these complex CS patients should be considered.
Open AccessPrevalence and Clinical Outcomes of Acute Noncardiac Organ Failure among Non-Acute Myocardial Infarction Cardiogenic Shock: A Nationwide Cohort Analysis
Background Noncardiac organ failure often complicates cardiogenic shock (CS). The results of cardiogenic shock caused by noncardiac organ failures in patients without acute myocardial infarction (AMI) are not well documented. Methods We examined the National Inpatient Sample (NIS) data from 2016 to 2020 to identify cases of CS and non-AMI CS-related hospitalizations. We divided both cohorts based on the number of acute noncardiac organ failures and evaluated the influence of organ failure on the primary outcome, which was in-hospital mortality. Results A total of 599,210 (100%) cardiogenic shock and 366,905 (61.2%) non-AMI CS hospitalizations were identified. Among those with non-AMI CS, 58,965 (16.07%) had no organ failure, 121,845 (33.21%) had a single organ failure, and 186,095 (50.72%) had a multiorgan failure. Acute Kidney Injury (AKI) was the most common non-cardiac organ failure (38.1%). Multiorgan failure was associated with an increased risk of in-hospital mortality (aOR: 4.91, 95% CI: 4.72-5.06, p Conclusions In non-acute myocardial infarction and all cardiogenic shock patients, AKI is the most common type of organ failure, and neurological failure was associated with the highest mortality rate. The presence of noncardiac multiorgan failure was found to be strongly associated with a higher mortality rate. This risk increased as more organs were affected. What Is New? ● Non-AMI patients bear a considerable load of non-cardiac organ failure, where AKI is the most prevalent form of organ failure. Additionally, neurological failure has the highest in-hospital mortality rate. ● A predictor model for calculating the probability of in-hospital mortality in all CS patients. ● Non-AMI cardiogenic shock and all cardiogenic shock patients are associated with higher morbidity, mortality, and resource utilization, as well as advanced circulatory support therapies, which increase as the number of affected organs increases. What are the Clinical Implications? ● Multi-organ failure in non-AMI CS can have worse cardiovascular outcomes. ● A multidisciplinary team’s involvement in managing these complex CS patients should be considered.
- 24 November 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (1)
Transcatheter versus surgical mitral valve repair in patients with mitral regurgitation
OBJECTIVES: The aim of this study was to compare clinical outcomes of transcatheter and surgical mitral valve repair (SMVr) in primary mitral regurgitation (MR) and MR with heart failure with reduced ejection fraction (HFrEF). METHODS: In this retrospective cohort study, we used the Nationwide Readmission Database to identify primary MR and MR with HFrEF patients who underwent transcatheter or SMVr from 2016 to 2019. A propensity score with 1:1 matching was applied. The primary outcome was a cumulative event rate of major adverse cardiovascular events (MACE), which was a composite of all-cause mortality, myocardial infarction, stroke, heart failure, cardiac arrest and mitral valve replacement. Other important secondary outcome was in-hospital mortality. RESULTS: After propensity score matching, 2187 matched pairs were found in the primary MR cohort and 2178 matched pairs were found in the MR-HFrEF cohort. Transcatheter mitral valve repair (TMVr) had significantly higher medium-term MACE compared with SMVr in both cohorts (primary MR: hazard ratio: 1.73, 95% confidence interval: 1.33–2.26, P ≤ 0.001; MR-HFrEF: hazard ratio: 2.00, 95% confidence interval: 1.58–2.54, P ≤ 0.001). TMVr showed similar in-hospital mortality in both cohorts. CONCLUSIONS: Although TMVr showed better short-term outcomes, it had significantly higher medium-term MACE than SMVr in both cohorts. Thus, shared decision-making should be performed for TMVr after discussing the benefits and risks in patients who can undergo SMVr.
- 24 November 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (1)
Transcatheter versus surgical mitral valve repair in patients with mitral regurgitation
OBJECTIVES: The aim of this study was to compare clinical outcomes of transcatheter and surgical mitral valve repair (SMVr) in primary mitral regurgitation (MR) and MR with heart failure with reduced ejection fraction (HFrEF). METHODS: In this retrospective cohort study, we used the Nationwide Readmission Database to identify primary MR and MR with HFrEF patients who underwent transcatheter or SMVr from 2016 to 2019. A propensity score with 1:1 matching was applied. The primary outcome was a cumulative event rate of major adverse cardiovascular events (MACE), which was a composite of all-cause mortality, myocardial infarction, stroke, heart failure, cardiac arrest and mitral valve replacement. Other important secondary outcome was in-hospital mortality. RESULTS: After propensity score matching, 2187 matched pairs were found in the primary MR cohort and 2178 matched pairs were found in the MR-HFrEF cohort. Transcatheter mitral valve repair (TMVr) had significantly higher medium-term MACE compared with SMVr in both cohorts (primary MR: hazard ratio: 1.73, 95% confidence interval: 1.33–2.26, P ≤ 0.001; MR-HFrEF: hazard ratio: 2.00, 95% confidence interval: 1.58–2.54, P ≤ 0.001). TMVr showed similar in-hospital mortality in both cohorts. CONCLUSIONS: Although TMVr showed better short-term outcomes, it had significantly higher medium-term MACE than SMVr in both cohorts. Thus, shared decision-making should be performed for TMVr after discussing the benefits and risks in patients who can undergo SMVr.